European Archives - Page 441 of 899 - European Medical Journal

Continue

Talking to Dr Gino Martini

Dr Gino Martini, Chief Scientist, Royal Pharmaceutical Society, covers the rapid data generation of COVID-19, the value of digital for HCPs, and why he thinks there will be much to reflect on after the pandemic has passed.
3 Mins
23rd June 2020

Newborn Screening: Now and in the Future

WHAT is the value of newborn screening (NBS) to the rare diseases community?…
2 Mins
23rd June 2020

Driving Care Pathways into the Future

ARTIFICIAL intelligence could one day form the backbone of healthcare, but with such a powerful technology looming on our horizon, what exactly does…
3 Mins
23rd June 2020

Disruptive Innovations in Clinical Research

New trends in clinical research and trial design were discussed, as well as challenges associated with the need to perform innovatively to advance…
8 Mins
23rd June 2020

Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative Colitis: The Missing Piece of The Puzzle?

In an interactive symposium moderated by Dr Cummings, the question: “Is early intervention with anti-TNF the key to achieving long-lasting remission…
June 2020

EMJ 5.2 2020

Welcome to EMJ 5.2! Our latest edition of EMJ highlights the experiences of patients with rare diseases, and the clinicians and organisations working…
8 Mins
23rd June 2020

Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction of Atherosclerotic Cardiovascular Disease Events

Atherosclerosis is an inflammatory disease and inflammation is crucial to all stages of atherogenesis. Targeting inflammation has the potential to reduce…
6 Mins
23rd June 2020

Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent Real-World Data

An enhanced understanding of real-world CL Gel usage could help improve the management of patients with MF-CTCL…
6 Mins
23rd June 2020

Data from the AUGUSTUS Trial Adds an Important Piece to the Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention

AF can increase stroke risk and is generally treated with OAC therapy, such as with a VKA or a direct OAC (DOAC). However, what if someone with AF…
8 Mins
23rd June 2020

Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: An Expert Clinical Consensus

PAH is a rare, progressive disorder with a number of aetiologies. Approximately 15–60 patients per million of the global population are affected…